BIO TCH ECO MED HUM LI LifeScience.News Sanofi’s $15 Billion Patent Cliff: A 2026 Strategic Roadmap Analyzing the Dupixent monopoly, the €2.24B Tolebrutinib setback, and the high-stakes race for Amlitelimab.